Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024 07:15 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024 06:00 ET
|
Entrada Therapeutics, Inc.
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs,...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class...
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase...
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada’s operational growth - BOSTON, Jan. 03,...
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second...
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s...